212 related articles for article (PubMed ID: 16255674)
1. Clinical status of agents being developed for leishmaniasis.
Berman J
Expert Opin Investig Drugs; 2005 Nov; 14(11):1337-46. PubMed ID: 16255674
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous leishmaniasis treatment.
Minodier P; Parola P
Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
[TBL] [Abstract][Full Text] [Related]
3. Current treatment approaches to leishmaniasis.
Berman J
Curr Opin Infect Dis; 2003 Oct; 16(5):397-401. PubMed ID: 14501991
[TBL] [Abstract][Full Text] [Related]
4. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
[TBL] [Abstract][Full Text] [Related]
5. The treatment of visceral leishmaniasis: safety and efficacy.
Jha RK; Sah AK; Shah DK; Sah P
JNMA J Nepal Med Assoc; 2013; 52(192):645-51. PubMed ID: 25327244
[TBL] [Abstract][Full Text] [Related]
6. Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.
Aguiar MG; Pereira AM; Fernandes AP; Ferreira LA
Antimicrob Agents Chemother; 2010 Nov; 54(11):4699-704. PubMed ID: 20713665
[TBL] [Abstract][Full Text] [Related]
7. Leishmaniasis: current status of available drugs and new potential drug targets.
Singh N; Kumar M; Singh RK
Asian Pac J Trop Med; 2012 Jun; 5(6):485-97. PubMed ID: 22575984
[TBL] [Abstract][Full Text] [Related]
8. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda.
Guerin PJ; Olliaro P; Sundar S; Boelaert M; Croft SL; Desjeux P; Wasunna MK; Bryceson AD
Lancet Infect Dis; 2002 Aug; 2(8):494-501. PubMed ID: 12150849
[TBL] [Abstract][Full Text] [Related]
9. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
10. Challenges and new discoveries in the treatment of leishmaniasis.
Singh S; Sivakumar R
J Infect Chemother; 2004 Dec; 10(6):307-15. PubMed ID: 15614453
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance in Indian visceral leishmaniasis.
Sundar S
Trop Med Int Health; 2001 Nov; 6(11):849-54. PubMed ID: 11703838
[TBL] [Abstract][Full Text] [Related]
12. Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy.
Darcis G; Van der Auwera G; Giot JB; Hayette MP; Tassin F; Arrese Estrada J; Cnops L; Moutschen M; de Leval L; Leonard P
BMC Infect Dis; 2017 Jul; 17(1):478. PubMed ID: 28687071
[TBL] [Abstract][Full Text] [Related]
13. Sitamaquine overcomes ABC-mediated resistance to miltefosine and antimony in Leishmania.
Pérez-Victoria JM; Bavchvarov BI; Torrecillas IR; Martínez-García M; López-Martín C; Campillo M; Castanys S; Gamarro F
Antimicrob Agents Chemother; 2011 Aug; 55(8):3838-44. PubMed ID: 21646479
[TBL] [Abstract][Full Text] [Related]
14. Advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years: a systematic literature review.
Almeida OL; Santos JB
An Bras Dermatol; 2011; 86(3):497-506. PubMed ID: 21738967
[TBL] [Abstract][Full Text] [Related]
15. Leishmaniasis: an update of current pharmacotherapy.
Sundar S; Chakravarty J
Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
[TBL] [Abstract][Full Text] [Related]
16. Current scenario of drug development for leishmaniasis.
Croft SL; Seifert K; Yardley V
Indian J Med Res; 2006 Mar; 123(3):399-410. PubMed ID: 16778319
[TBL] [Abstract][Full Text] [Related]
17. Miltefosine and cutaneous leishmaniasis.
Machado PR; Penna G
Curr Opin Infect Dis; 2012 Apr; 25(2):141-4. PubMed ID: 22248979
[TBL] [Abstract][Full Text] [Related]
18. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
[TBL] [Abstract][Full Text] [Related]
19. [Oral miltefosine to treat leishmaniasis].
Soto J; Soto P
Biomedica; 2006 Oct; 26 Suppl 1():207-17. PubMed ID: 17361856
[TBL] [Abstract][Full Text] [Related]
20. Miltefosine for new world cutaneous leishmaniasis.
Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
